XOMA (XOMA)
(Delayed Data from NSDQ)
$25.41 USD
+0.05 (0.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $25.68 +0.27 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
XOMA 25.41 +0.05(0.20%)
Will XOMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XOMA
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
Other News for XOMA
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Xoma earns $9M milestone as FDA grants approval of Day One's NDA for OJEMDA
Wall Street Analysts Are Bullish on Top Healthcare Picks
Actym Therapeutics Appoints Thomas Smart as CEO
Day One wins FDA nod for brain cancer therapy, Ojemda